Loading...

Cytokinetics, Incorporated

CYTKNASDAQ
Healthcare
Biotechnology
$33.04
$0.00(0.00%)

Cytokinetics, Incorporated (CYTK) Stock Overview

Explore Cytokinetics, Incorporated’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 71.3/100

Key Financials

Market Cap4B
P/E Ratio-6.34
EPS (TTM)$-5.29
ROE8.01%
Fundamental Analysis

AI Price Forecasts

1 Week$32.45
1 Month$35.26
3 Months$34.03
1 Year Target$78.02

CYTK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cytokinetics, Incorporated (CYTK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $78.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.34 and a market capitalization of 4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
145.34%
145.34%
Profit Growth
$-5.19
12.03%
EPS Growth
$-5.19
3.49%
Operating Margin
-2943.30%
8.07%
ROE
801.26%
12.03%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
4
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$55.00
Average$75.50
High$120.00

Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CEO

Robert I. Blum

Employees

498

Headquarters

350 Oyster Point Boulevard, South San Francisco, CA

Founded

2004

Frequently Asked Questions

;